CDX General Discussion 2025, page-159

We are back at $21mil MC, with the billion $ + potential here.

The legacy products were only able to be used by trained clinicians, and did great numbers, thousands of studies completed proving Sphygmocor is the golden standard. Now we have the Pulse with Sphygmocor tech, in the form of a traditional BP monitor that anyone can use.

For those unaware, the unique vascular biomarkers that the Pulse measure are listed here;
https://cardiex.com/products/conneqt-pulse/

And for those interested in scholarly articles about Sphygmocor, google Scholar has over 17,000 listed;
https://scholar.google.com.au/scholar?hl=en&as_sdt=0%2C5&q=sphygmocor&btnG=&oq=sphygmo

Whilst we are in the dumps share price wise, should Sphygmocor tech replicate its previous success with the Pulse, this could be the perfect entry to see the technology take off at a new scale, previous moves show how excited the market gets with a slither of a positive announcement.

Strategic investment would be perfect at this time, the question marks over the cash position are why the share price is so low IMO, sales have been positive for a brand new product taking off. Imagine it gamified life MyZone for example. I think it's a speculative buy here, support line is like 4.8c but there's been significant amounts exchanged above mid-high 5's, as always DYOR.